VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Saturday, January 3, 2026

Wide Moat Stocks Home My Collections

Stock Comparison

Constellation Software Inc. vs Gilead Sciences, Inc.

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Constellation Software Inc.

CSU · Toronto Stock Exchange

Market cap (USD)—

Gross margin (TTM)—

Operating margin (TTM)—

Net margin (TTM)—

SectorTechnology

Industry—

CountryCA

Data as of2026-01-02

Moat score

74/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Constellation Software Inc.'s moat claims, evidence, and risks.

View CSU analysis

Gilead Sciences, Inc.

GILD · NASDAQ Global Select Market

Market cap (USD)$150.9B

Gross margin (TTM)78.7%

Operating margin (TTM)36.1%

Net margin (TTM)27.9%

SectorHealthcare

IndustryDrug Manufacturers - General

CountryUS

Data as of2025-12-30

Moat score

74/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.

View GILD analysis

Comparison highlights

Moat score: both at 74 / 100.
Segment focus: Constellation Software Inc. has 6 segments; Gilead Sciences, Inc. has 5 segments (68.5% in HIV).
Primary market structure: Competitive vs Oligopoly. Pricing power: Moderate vs Moderate.
Moat breadth: Constellation Software Inc. has 3 moat types across 2 domains; Gilead Sciences, Inc. has 8 across 3.

Primary market context

Constellation Software Inc.

Volaris Operating Group

Market

Vertical market software (VMS) portfolios across diverse industries (Volaris)

Geography

Global (North America, Continental Europe, UK, Australia, South America, Africa)

Customer

Organizations in specific verticals (mix of public and private sector)

Role

Vertical market software vendor (application provider + long-term maintainer)

Gilead Sciences, Inc.

HIV

Market

HIV treatment and prevention medicines (antiretroviral therapy and PrEP)

Geography

Global (U.S. and Europe are major markets)

Customer

Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies

Role

Drug developer and marketing authorization holder

Revenue share

68.5%

Side-by-side metrics

Constellation Software Inc.

Gilead Sciences, Inc.

Ticker / Exchange

CSU - Toronto Stock Exchange

GILD - NASDAQ Global Select Market

Market cap (USD)

n/a

$150.9B

Gross margin (TTM)

n/a

78.7%

Operating margin (TTM)

n/a

36.1%

Net margin (TTM)

n/a

27.9%

Sector

Technology

Healthcare

Industry

n/a

Drug Manufacturers - General

HQ country

Primary segment

Volaris Operating Group

HIV

Market structure

Competitive

Oligopoly

Market share

n/a

50%-60% (reported)

HHI estimate

n/a

Pricing power

Moderate

Moat score

74 / 100

Moat domains

Demand, Supply

Demand, Legal, Supply

Last update

2026-01-02

2025-12-30

Moat coverage

Shared moat types

Switching Costs General

Constellation Software Inc. strengths

Installed Base ConsumablesOperational Excellence

Gilead Sciences, Inc. strengths

Habit DefaultIP Choke PointService Field NetworkCapex Knowhow ScaleCompliance AdvantageRegulated Standards PipeBrand Trust

Segment mix

Constellation Software Inc. segments

Full profile >

Volaris Operating Group

Competitive

n/a

Harris Operating Group

Competitive

n/a

Topicus.com Operating Group

Competitive

n/a

Jonas Operating Group

Competitive

n/a

Perseus Operating Group

Competitive

n/a

Vela Operating Group

Competitive

n/a

Gilead Sciences, Inc. segments

Full profile >

HIV

Oligopoly

68.5%

Oncology (Cell Therapy + Trodelvy)

Oligopoly

11.5%

Liver Disease

Oligopoly

10.6%

Veklury (Remdesivir)

Competitive

6.3%

Other Products

Competitive

3.1%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.